Intravenous Zotatifin in Adults With Mild or Moderate COVID-19
Public ClinicalTrials.gov record NCT04632381. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Trial of Intravenous Zotatifin in Adults With Mild or Moderate Coronavirus Disease 2019 (COVID-19)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
To evaluate the safety and tolerability, the antiviral activity, and plasma pharmacokinetics (PK) of zotatifin administered intravenously (IV) to adults with mild or moderate COVID-19.
Study identification
- NCT ID
- NCT04632381
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 36 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 64 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 30, 2021
- Primary completion
- Jan 11, 2023
- Completion
- Sep 21, 2023
- Last update posted
- Oct 4, 2023
2021 – 2023
United States locations
- U.S. sites
- 4
- U.S. states
- 3
- U.S. cities
- 4
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pinnacle Research Group | Anniston | Alabama | 36207 | — |
| Cullman Clinical Trials | Cullman | Alabama | 35055 | — |
| Tampa General Hospital | Tampa | Florida | 33606 | — |
| National Institute of Allergy and Infectious Diseases | Bethesda | Maryland | 20814 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Corona Virus Infection trials
Other public records listing Corona Virus Infection. Sorted by last update posted; newest first. Not a recommendation.
- NCT04579588: Understanding Immunity to the Flu Vaccine in COVID-19 Patients Recruiting
- NCT04360538: Long Term Outcomes of Patients With COVID-19 Active, not recruiting
- NCT04448145: Determinants of SARS (Severe Acute Respiratory Syndrome)-COV2 (COVID-19) Persistence After Convalescence Recruiting
- NCT04705766: KIDney Injury in Times of COVID-19 (KIDCOV) Recruiting
- NCT04359836: A Study to Explore the Role of Gut Flora in COVID-19 Infection Recruiting
- NCT04388605: Assessing the Safety of Pregnancy In the CoRonavirus (COVID-19) pandEmic Active, not recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04632381, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 4, 2023 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04632381 live on ClinicalTrials.gov.